Co-Authors
This is a "connection" page, showing publications co-authored by Kevin Gray and Rachel Tomko.
Connection Strength
10.169
-
Sex Differences in Subjective and Behavioral Responses to Stressful and Smoking Cues Presented in the Natural Environment of Smokers. Nicotine Tob Res. 2020 01 27; 22(1):81-88.
Score: 0.721
-
Depressive symptoms and cannabis use in a placebo-controlled trial of N-Acetylcysteine for adult cannabis use disorder. Psychopharmacology (Berl). 2020 Feb; 237(2):479-490.
Score: 0.711
-
An electronic, smart lighter to measure cigarette smoking: A pilot study to assess feasibility and initial validity. Addict Behav. 2019 11; 98:106052.
Score: 0.695
-
Methods to reduce the incidence of false negative trial results in substance use treatment research. Curr Opin Psychol. 2019 12; 30:35-41.
Score: 0.673
-
Corrigendum to The role of depressive symptoms in treatment of adolescent cannabis use disorder with N-Acetylcysteine Addictive Behaviors 85 (2018) 26-30. Addict Behav. 2019 Feb; 89:263.
Score: 0.658
-
N-acetylcysteine: A potential treatment for substance use disorders. Curr Psychiatr. 2018 06; 17(6):30-36, 41-42, 55.
Score: 0.643
-
The role of depressive symptoms in treatment of adolescent cannabis use disorder with N-Acetylcysteine. Addict Behav. 2018 10; 85:26-30.
Score: 0.642
-
Incremental validity of estimated cannabis grams as a predictor of problems and cannabinoid biomarkers: Evidence from a clinical trial. Drug Alcohol Depend. 2018 01 01; 182:1-7.
Score: 0.618
-
Alcohol consumption as a predictor of reactivity to smoking and stress cues presented in the natural environment of smokers. Psychopharmacology (Berl). 2017 Feb; 234(3):427-435.
Score: 0.578
-
Personalizing substance use treatment based on pre-treatment impulsivity and sensation seeking: A review. Drug Alcohol Depend. 2016 Oct 01; 167:1-7.
Score: 0.566
-
Distress tolerance and reactivity to negative affective cues in naturalistic environments of cannabis-using emerging adults. Drug Alcohol Depend. 2022 09 01; 238:109588.
Score: 0.214
-
Varenicline as a treatment for cannabis use disorder: A placebo-controlled pilot trial. Drug Alcohol Depend. 2021 12 01; 229(Pt B):109111.
Score: 0.202
-
Evaluating N-acetylcysteine for early and end-of-treatment abstinence in adult cigarette smokers. Drug Alcohol Depend. 2021 08 01; 225:108815.
Score: 0.199
-
Cannabis and Alcohol Co-Use in a Smoking Cessation Pharmacotherapy Trial for Adolescents and Emerging Adults. Nicotine Tob Res. 2020 07 16; 22(8):1374-1382.
Score: 0.186
-
Making pharmacotherapy trials for substance use disorder more efficient: Leveraging real-world data capture to maximize power and expedite the medication development pipeline. Drug Alcohol Depend. 2020 04 01; 209:107897.
Score: 0.181
-
Efficacy and Safety of Varenicline for Adolescent Smoking Cessation: A Randomized Clinical Trial. JAMA Pediatr. 2019 12 01; 173(12):1146-1153.
Score: 0.178
-
Measuring Within-Individual Cannabis Reduction in Clinical Trials: A Review of the Methodological Challenges. Curr Addict Rep. 2019 Dec; 6(4):429-436.
Score: 0.178
-
Adolescent Substance Use Disorder Treatment: an Update on Evidence-Based Strategies. Curr Psychiatry Rep. 2019 09 14; 21(10):96.
Score: 0.176
-
Pharmacological Treatment of Youth Substance Use Disorders. J Child Adolesc Psychopharmacol. 2019 08; 29(7):559-572.
Score: 0.171
-
Blunts versus joints: Cannabis use characteristics and consequences among treatment-seeking adults. Drug Alcohol Depend. 2019 05 01; 198:105-111.
Score: 0.170
-
Tobacco use during cannabis cessation: Use patterns and impact on abstinence in a National Drug Abuse Treatment Clinical Trials Network study. Drug Alcohol Depend. 2018 11 01; 192:59-66.
Score: 0.163
-
Acceptability and compliance with a remote monitoring system to track smoking and abstinence among young smokers. Am J Drug Alcohol Abuse. 2018; 44(5):561-570.
Score: 0.160
-
Using REDCap for ambulatory assessment: Implementation in a clinical trial for smoking cessation to augment in-person data collection. Am J Drug Alcohol Abuse. 2019; 45(1):26-41.
Score: 0.158
-
The effect of N-acetylcysteine on alcohol use during a cannabis cessation trial. Drug Alcohol Depend. 2018 04 01; 185:17-22.
Score: 0.157
-
Reductions in cannabis use are associated with improvements in anxiety, depression, and sleep quality, but not quality of life. J Subst Abuse Treat. 2017 10; 81:53-58.
Score: 0.152
-
A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults. Drug Alcohol Depend. 2017 08 01; 177:249-257.
Score: 0.150
-
Alcohol use during a trial of N-acetylcysteine for adolescent marijuana cessation. Addict Behav. 2016 12; 63:172-7.
Score: 0.142
-
Low Pretreatment Impulsivity and High Medication Adherence Increase the Odds of Abstinence in a Trial of N-Acetylcysteine in Adolescents with Cannabis Use Disorder. J Subst Abuse Treat. 2016 Apr; 63:72-7.
Score: 0.136
-
N-acetylcysteine does not alter neurometabolite levels in non-treatment seeking adolescents who use alcohol heavily: A?preliminary randomized clinical trial. Neuropsychopharmacology. 2023 Mar 06.
Score: 0.056
-
Determining the impact of cannabis use and severity on tobacco cessation outcomes: study protocol for a prospective tobacco treatment trial. BMC Psychol. 2023 Jan 25; 11(1):25.
Score: 0.055
-
Characterization of Salivary Progesterone in Female Smokers. Nicotine Tob Res. 2022 10 26; 24(11):1829-1833.
Score: 0.055
-
Assessment of patient perception of treatment assignment and patient-reported outcomes in a cannabis use disorder trial. Am J Drug Alcohol Abuse. 2022 Nov 02; 48(6):651-661.
Score: 0.054
-
A pilot feasibility study of a behavioral intervention for nicotine vaping cessation among young adults delivered via telehealth. Drug Alcohol Depend. 2022 03 01; 232:109311.
Score: 0.052
-
The estimand framework and its application in substance use disorder clinical trials: a case study. Am J Drug Alcohol Abuse. 2021 11 02; 47(6):658-663.
Score: 0.051
-
Correspondence Between Perceived Pubertal Development and Hormone Levels in 9-10 Year-Olds From the Adolescent Brain Cognitive Development Study. Front Endocrinol (Lausanne). 2020; 11:549928.
Score: 0.049
-
Examining sex, adverse childhood experiences, and oxytocin on neuroendocrine reactivity in smokers. Psychoneuroendocrinology. 2020 10; 120:104752.
Score: 0.046
-
Increases in endogenous progesterone attenuate smoking in a cohort of nontreatment seeking women: An exploratory prospective study. Addict Biol. 2021 03; 26(2):e12918.
Score: 0.046
-
The influence of gender and oxytocin on stress reactivity, cigarette craving, and smoking in a randomized, placebo-controlled laboratory relapse paradigm. Psychopharmacology (Berl). 2020 Feb; 237(2):543-555.
Score: 0.045
-
Behavioral Treatments for Adolescent Cannabis Use Disorder: a Rationale for Cognitive Retraining. Curr Addict Rep. 2019 Dec; 6(4):437-442.
Score: 0.044
-
Impact of cannabis legalization on treatment and research priorities for cannabis use disorder. Int Rev Psychiatry. 2018 06; 30(3):216-225.
Score: 0.040